2010
DOI: 10.1177/0333102410390398
|View full text |Cite
|
Sign up to set email alerts
|

Sumatriptan as a treatment for cyclic vomiting syndrome: A clinical trial

Abstract: We conclude that sumatriptan has potential efficacy in treating of patients with CVS.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
39
1
2

Year Published

2012
2012
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 70 publications
(42 citation statements)
references
References 12 publications
0
39
1
2
Order By: Relevance
“…Patients with CVS are usually treated with either antidepressants, antimigrainous or antiepileptic medications [17,[22][23][24]. However, this cohort of patients is unique in that the majority of patients were only treated symptomatically.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Patients with CVS are usually treated with either antidepressants, antimigrainous or antiepileptic medications [17,[22][23][24]. However, this cohort of patients is unique in that the majority of patients were only treated symptomatically.…”
Section: Discussionmentioning
confidence: 99%
“…Other drugs used as prophylactic treatment include propranolol [15], phenobarbitone [16] and coenzyme Q [14]. Furthermore, there is evidence for the use of sumatriptan [17] as an acute abortive therapy.…”
Section: Introductionmentioning
confidence: 99%
“…Treatment should be initiated at the earliest signs of nausea. Sumatriptan (a 5-hydroxytryptamine (HT)- 1 receptor antagonist) has been shown to have some efficacy in aborting the attacks during the prodromal phase,12 when administered, intranasally, subcutaneously or even orally, particularly in patients with a family history of migraine 34 35 49…”
Section: Treatmentmentioning
confidence: 99%
“…Other triptans have also been studied in the adolescent and Cyclic vomiting syndrome which has been linked to migraine was shown to respond to sumatriptan 3 mg subcutaneously and with a 20 mg nasal spray [17]. Other possibly related migraine disorders have not been studied.…”
Section: Recent Updates In the Use Of Triptans In The Pediatric Populmentioning
confidence: 99%